title: Dexmedetomidine could enhance surgical satisfaction in Trans-sphenoidal resection of pituitary adenoma.
abstract: Excessive bleeding is an unwanted complication of trans-sphenoidal resection of pituitary adenoma due to increases in intracranial pressure (ICP) and hemodynamic instability. Dexmedetomidine (Dex) anα2-agonists is the drug of choice in intensive care units (ICU) and cardiac surgeries to control abrupt changes in hemodynamic. Severe cardiovascular responses occur during trans-sphenoidal resection (TSR) of the pituitary adenoma despite adequate depth of anesthesia. The aim of this paper was to determine the effect of Dexmedetomidine on bleeding as primary outcome, and surgeon's satisfaction and hemodynamic stability as secondary outcomes in patients undergoing trans-sphenoidal resection of pituitary adenoma.
  
  
  
  Total numbers of 60 patients between 18-65 years old and candidate for elective trans-sphenoidal resection of pituitary adenoma were randomLy allocated to two groups; Dexmedetomidine infusion (0.6µg/kg/hour) or normal saline infusion. Mean arterial pressure (MAP), heart rate (HR), dose of hypnotics and narcotics during surgery, bleeding, and surgeon's satisfaction were recorded.
  
  
  
  Propofol maintenance dose (µg/kg/min) and total Fentanyl use (µg) were significantly lower in Dex group compare to control group (P=0.01 and 0.003, respectively). Total bleeding amount during operation in Dex group was significantly lower than control group (P=0.012). Surgeon's satisfaction was significantly higher in Dex group at the end of surgery. MAP and heart rate throughout surgery were significantly lower in Dex group compare to control group (P=0.001).
  
  
  
  Dexmedetomidine infusion (0.6µg/kg/hour) could reduce bleeding and provide surgeon's satisfaction during trans-sphenoidal resection of pituitary adenoma.
authors.affiliation: Department of Anesthesiology, Shahid Beheshti University of Medical Sciences, Loghman Hospital, Tehran, Iran - k_mottaghi@sbmu.ac.ir.
authors.forename: Alireza
authors.initials: A
authors.lastname: Salimi
authors.forename: Guive
authors.initials: G
authors.lastname: Sharifi
authors.forename: Houshang
authors.initials: H
authors.lastname: Bahrani
authors.forename: Seyed A
authors.initials: SA
authors.lastname: Mohajerani
authors.forename: Alireza
authors.initials: A
authors.lastname: Jafari
authors.forename: Farhad
authors.initials: F
authors.lastname: Safari
authors.forename: Maryam
authors.initials: M
authors.lastname: Jalessi
authors.forename: Alireza
authors.initials: A
authors.lastname: Mirkheshti
authors.forename: Kamran
authors.initials: K
authors.lastname: Mottaghi
mesh_terms: D000236:Adenoma / Q000601:surgery*; D000328:Adult; D000368:Aged; D000758:Anesthesia / Q000379:methods; D020927:Dexmedetomidine / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006339:Heart Rate / Q000187:drug effects; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D006993:Hypnotics and Sedatives / Q000627:therapeutic use; D008297:Male; D008875:Middle Aged; D010549:Personal Satisfaction; D010911:Pituitary Neoplasms / Q000601:surgery*; D015742:Propofol / Q000627:therapeutic use
chemical_list: D006993:Hypnotics and Sedatives; D020927:Dexmedetomidine; D015742:Propofol